Angiogenesis Inhibition by Rüdiger LierschAngiogenesis Inhibition by Rüdiger Liersch

Angiogenesis Inhibition

EditorRüdiger Liersch, Wolfgang E. Berdel, Torsten Kessler

Paperback | May 5, 2012

Pricing and Purchase Info

$282.80 online 
$297.95 list price save 5%
Earn 1414 plum® points

In stock online

Ships free on orders over $25

Not available in stores


Angiogenesis is attracting increased scientific and clinical interest. The identification of novel mediators and targeting molecules has led to significant progress in our understanding of tumor angiogenesis and tumor vessel targeting. Important advances in cancer treatment have already emerged, and in the future, blood vessel targeting will play a significant role within individualized therapeutic strategies. This volume provides a general overview of the latest developments in angiogenesis inhibition in cancer. All aspects from the bench to the bedside are considered, with detailed attention both to basic research and to its translation into clinical practice. Individual chapters are devoted to the roles of angiopoietins, HIF-1a, chemokines, PDGF and VEGF, and vascular integrins. The latest results of clinical trials are presented, and various advanced targeting strategies are discussed. This book will be invaluable to all who wish to learn of the most recent advances in this exciting field.
Title:Angiogenesis InhibitionFormat:PaperbackDimensions:248 pages, 9.25 × 6.1 × 0.07 inPublished:May 5, 2012Publisher:Springer Berlin HeidelbergLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:3642261434

ISBN - 13:9783642261435

Look for similar items by category:


Table of Contents

Introduction. Angiopoietins.- HIF-1a and cancer therapy.- Chemokines.- Platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy.- Vascular integrins: therapeutic and imaging targets of tumor angiogenesis. PDGF and vessel maturation.- Lymphangiogenesis in cancer: current perspectives.- Therapeutic compounds in clinical studies of Phase III trials and beyond.- Metronomic chemotherapy - principles and lessons learned from applications in the treatment of metastatic prostate cancer.- Targeting inflammatory cells to improve anti-VEGF therapies in oncology.- Antibody-based vascular tumor targeting. Caveolae and cancer.